Treats relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified…. Sold as Columvi. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Glofitamab-Gxbm (sold as Columvi), first approved Jun 15, 2023, with 0 new uses approved and 0 published complete response letters.
| Columvi | Part B | $77.6M | +89% | 491 |
| Columvi | Part D | $548K | New | 0 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit LymphomaRecurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements · National Cancer Institute (NCI) | Phase 2 / Phase 3 | Not yet recruiting | Jul 24, 2026 |
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · National Cancer Institute (NCI) | Phase 1 | Recruiting | Jun 16, 2026 |
| Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell LymphomaAnn Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma · National Cancer Institute (NCI) | Phase 1 | Not yet recruiting | Mar 3, 2026 |
| Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell TherapyRecurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma · National Cancer Institute (NCI) | Phase 2 | Recruiting | Jun 4, 2025 |
| Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System LymphomaPrimary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma · City of Hope Medical Center | Phase 1 | Recruiting | Apr 10, 2025 |
| Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell LymphomaAggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma · University of Washington | Phase 1 / Phase 2 | Active, not recruiting | Jan 18, 2020 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jun 15, 2023 | ColumviBLA 761309 · New molecular entity | Genentech Inc | 4 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA